ライフサイエンスコーパス: tissue factor

1 ellular adhesion molecule-1, E-selectin, and tissue factor.

2 tive coagulopathy initiated by exposed brain tissue factor.

3 logic expression of the procoagulant protein tissue factor.

4 hat it must compete with endogenous FVII for tissue factor.

5 on by factor VIIa in the presence of soluble tissue factor.

6 macrophages, but enhanced the expression of tissue factor.

7 ted Thrombogram assay triggered with 1microM tissue factor.

8 genic/protumourigenic transmembrane receptor Tissue Factor.

9 sma perfused through a capillary coated with tissue factor.

10 None of the 4 types of EVs presented tissue factor.

11 tic (or both) solid tumours known to express tissue factor.

12 lified TG initiated by low concentrations of tissue factor.

13 easome activity, demographic, medication, or tissue factors.

14 For blood clotting on collagen/tissue factor (1 TF-molecule/mum2) at 200 s-1 wall shear

15 of CpG DNA on the expression and activity of tissue factor, a key initiator of coagulation and tissue

16 ted CD8+ T cells induce monocytes to express tissue factor, a potent activator of coagulation.

17 was cleaved and activated by thrombin, while tissue factor, a potent thrombin activator, colocalized

18 (FXa) via a slow-tight binding mechanism and tissue factor-activated FVII (TF-FVIIa) via formation of

19 In addition, microvesicle tissue factor activity and interleukin-8 levels were sig

20 etween plasma interleukin-8 and microvesicle tissue factor activity measured on admission in patients

21 g the redox-sensitive probe dihydroethidium, tissue factor activity using an enzymatic Tenase assay,

22 ed on ICU day 1, only increased microvesicle tissue factor activity was significantly associated with

23 Microvesicle tissue factor activity, thrombin-antithrombin complexes,

24 senger RNA and protein levels, as well as in tissue factor activity.

25 in 1) quiescent plasma exposed to patches of tissue factor and 2) plasma perfused through a capillary

26 ulation and complement activation (including tissue factor and C5a), and multifocal intra-alveolar fi

27 ionally increased and express high levels of tissue factor and CD62P in HIV-1 infection.

28 eading to local delivery of monocyte-derived tissue factor and cytokines.

29 -kappaB levels and NF-kappaB-dependent genes tissue factor and IL-6 were increased compared with cont

30 lic artery (26%), with reduced expression of Tissue factor and MMP9.

31 L5 but not L1 induced tissue factor and P-selectin expression in human aortic

32 eural administration of MPM cells expressing tissue factor and PAR1 but lacking EPCR and PAR2 (F2RL1)

33 nd protein C is dependent on the presence of tissue factor and platelets but not on coagulation facto

34 Leukocytes can be induced to express tissue factor and release proinflammatory and procoagula

35 -NGR consists of the extracellular domain of tissue factor and the peptide GNGRAHA, a ligand of the s

36 chanisms, coagulation factors, in particular tissue factor and thrombin, might also participate in th

37 hese data, we detected increased circulating tissue factor and thrombin-antithrombin complexes in pat

38 helial cell was challenged with CpG DNA, and tissue factor and tissue factor pathway inhibitor expres

39 Toll-like receptor 9 shifted the balance of tissue factor and tissue factor pathway inhibitor toward

40 pendently associated with elevated levels of tissue factor and tissue plasminogen activator.

41 coagulant activation with high expression of tissue factor and vWF, and low expression of the ectonuc

42 ike cells in human tissues in vivo, and that tissue factors and Aiolos were required for this process

43 Specifically, we consider various tumor tissue factors and physicochemical factors that can affe

44 elial inflammation, white blood cell-derived tissue factor, and ample red blood cell incorporation.

45 uction, including high-mobility group box-1, tissue factor, and IL-1beta.

46 PAR-2 ligands, mast cell tryptase, trypsin, tissue factor, and kallikrein (KLK) 5 and KLK14, were as

47 ch as alphaIIbbeta3, alphavbeta3, GPIbalpha, tissue factor, and thrombospondin.

48 ment with inhibitory oligonucleotide or anti-tissue factor antibody or genetic deletion of TLR9 preve

49 This effect was reversed with an anti-tissue factor antibody.

50 To explore the possibility of using tissue factor as a target for an antibody-drug conjugate

51 Alternatively spliced tissue factor (asTF) is a novel isoform of full-length t

52 The results for tissue factor-bearing microparticles are heterogeneous:

53 dhesion of neutrophils in venules, generated tissue factor-bearing microparticles, shortened plasma-c

54 flammatory cells through their expression of tissue factor can directly affect hemostasis and thrombo

55 ouse model to investigate the involvement of tissue factor, coagulation factor XII, platelets, and ne

56 Tissue factor, coagulation factor XII, platelets, and ne

57 rombin potential was markedly reduced at low-tissue factor concentration, and failure to correct with

58 calibrated platelet aggregation model with a tissue-factor/contact pathway coagulation cascade, repre

59 on was abolished in mice with liver-specific tissue factor deficiency, pinpointing the trigger of coa

60 Platelet-specific APLs optimally supported tissue factor-dependent coagulation in human plasma, vs.

61 activated monocytes trigger coagulation in a tissue factor-dependent manner, it remains uncertain whe

62 pressed EPCR and PAR1 with minimal levels of tissue factor did not increase their limited tumorigenic

63 high wall shear stresses, and plaque-derived tissue factor driving thrombin production.

64 pecific 6 (Gas6) regulates the expression of tissue factor during venous thrombosis, and (2) cancer p

65 this study, we investigated the influence of tissue factor, endothelial cell protein C receptor (EPCR

66 On the contrary, addition of tissue factor enhanced clot contraction, mimicking the e

67 endent of the shear rate; (3) a mechanism of tissue factor-enhanced activation of the intrinsic coagu

68 , using human MPM cells that lack or express tissue factor, EPCR or PAR1, and an orthotopic nude mous

69 ne whether circulating extracellular vesicle tissue factor (EVTF) activity levels associates with DIC

70 termine if circulating extracellular vesicle tissue factor (EVTF) activity levels associates with DIC

71 Tissue factor expressed by eosinophils can induce activa

72 d clot contraction, mimicking the effects of tissue factor expressed on the activated monocytes.

73 ey show how EPCR can attenuate the growth of tissue factor-expressing tumor cells.

74 explained by the ability of Gas6 to promote tissue factor expression and activity.

75 nuclear factor-kappaB-mediated increases in tissue factor expression at both messenger RNA and prote

76 ctively (p < 0.05), and attenuated monocytic tissue factor expression by 33% (p < 0.001).

77 IF1alpha were also associated with increased tissue factor expression in human breast tumor samples.

78 all PDX models, including models that showed tissue factor expression in only 25% to 50% of the tumor

79 No specific tissue factor expression level was required for inclusio

80 Inhibition of tissue factor expression or its inactivation on the surf

81 vity in EC induces an increase in ICAM-1 and tissue factor expression through the upregulation of p38

82 In vitro, thrombin-induced tissue factor expression was reduced in Gas6(-/-) endoth

83 Tissue factor expression was significantly reduced in th

84 ivation (proportions of monocyte subsets and tissue factor expression) and T-cell activation (express

85 nograft (PDX) models with variable levels of tissue factor expression, derived from seven different s

86 Granulocyte tissue factor expression, formation of thrombin-antithro

87 in vitro and in vivo, which was dependent on tissue factor expression.

88 C3 deposition, C5a release, and procoagulant tissue-factor expression.

89 The procoagulant protein tissue factor (F3) is a powerful growth promoter in many

90 I) is an anticoagulant protein that inhibits tissue factor-factor VIIa (TF-fVIIa) and factor Xa (fXa)

91 We examined whether the tissue factor/factor VIIa complex initiates the coagulat

92 In fact, inhibition of the tissue factor/factor VIIa complex reduced mortality in a

93 oagulant protein c2, a powerful inhibitor of tissue factor/factor VIIa-dependent coagulation (n = 6),

94 Tissue factor/factor VIIa-dependent pathway initiates co

95 the factor Xa (FXa)-dependent inhibition of tissue factor/factor VIIa.

96 lin M, immunoglobulin G, complement, fibrin, tissue factor, fibrinogen-like protein 2, tissue plasmin

97 Full-length tissue factor (flTF), the coagulation initiator, is over

98 endothelial activation/damage, production of tissue factor from monocytes, increased platelet activat

99 However, neutrophils may passively acquire tissue factor from monocytes.

100 entified a chromosome 3 locus containing the tissue factor gene (F3).

101 Transcription and protein expression of tissue factor (gene name, F3) were downregulated in resp

102 Three tissue factor HuMab, that induced efficient inhibition o

103 n vivo outcomes, such as the upregulation of tissue factor in endothelial cell systems by compounds l

104 The expression of tissue factor in intestinal macrophages was also unique

105 compstatin Cp40 inhibited the expression of tissue factor in neutrophils.

106 ly shorten the thrombin burst in response to tissue factor in platelet-rich plasma (PRP) from patient

107 p formation, fibrin, and local activation of tissue factor in the thrombotic milieu.

108 gressive MPM cells engineered to overexpress tissue factor increased their tumorigenicity.

109 formation; (2) a surface-independent role of tissue factor, independent of the shear rate; (3) a mech

110 Clotting stimulation by immobilized tissue factor induced localized thrombin activity impuls

111 d with recombinant soluble TM showed reduced tissue factor-induced thrombin generation.

112 flammatory cytokine TNFalpha which initiates tissue factor induction and subsequent blood clotting.

113 th separate MR imaging measurements of other tissue factors influencing T2*, it might be possible to

114 and thromboelastography was used to measure tissue factor-initiated fibrin formation and tissue-plas

115 transfusion, no thrombin was generated in a tissue factor-initiated whole blood clotting assay unles

116 Tissue factor initiates the process of thrombosis and ac

117 Other studies showed that incorporation of tissue factor into the envelope of herpes simplex virus

118 D-dimer and soluble tissue factor levels were significantly elevated in elit

119 in plasma thrombin-antithrombin complex and tissue factor levels.

120 elamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol

121 c factors expressed on tumor cells influence tissue factor-mediated effects on cancer progression.

122 Finally, higher tissue factor messenger RNA levels were measured in the

123 e heparin-dependent platelet aggregation and tissue factor messenger RNA synthesis by monocytes.

124 le 1, vascular cell adhesion molecule 1, and tissue factor messenger RNA.

125 ant activity was assessed by a functional MP-tissue factor (MP-TF) assay.

126 rombin generation by decidual cell-expressed tissue factor often accompany abruptions.

127 tive form, as induced either by its cofactor tissue factor or a covalent active site inhibitor.

128 When they carry tissue factor or coagulation inhibitors, they participat

129 Suppression of tissue factor or PAR1 expression in these cells markedly

130 Inhibition of either tissue factor or thrombin in WT mice also significantly

131 elta12 interfere with polyphosphate- but not tissue factor- or nucleic acid-driven thrombin formation

132 In contrast, tissue factor overexpression in nonaggressive MPM cells

133 in (P = 0.009), and diminished expression of tissue factor (P = 0.005) and fibrinogen-like protein 2

134 bin generation thresholds across a series of tissue factor patch sizes or wall shear rates.

135 C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22alpha-TFPI) were su

136 r F5(L) (F5(L/L) ) and haploinsufficient for tissue factor pathway inhibitor (Tfpi(+/-) ).

137 ompared to HC, as were MPs expressing TF and Tissue Factor Pathway Inhibitor (TFPI) (all p < 0.0001).

138 fibrin formation was associated with reduced tissue factor pathway inhibitor (TFPI) expression and in

139 Tissue factor pathway inhibitor (TFPI) is a critical ant

140 Tissue factor pathway inhibitor (TFPI) is a Kunitz-type

141 Tissue factor pathway inhibitor (TFPI) is an anticoagula

142 Tissue factor pathway inhibitor (TFPI) plays an importan

143 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI) that critically r

144 in vitro thrombin generation, and levels of tissue factor pathway inhibitor (TFPI) were strongly inc

145 Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the

146 ein Z-dependent protease inhibitor (ZPI) and tissue factor pathway inhibitor (TFPI), effectively inhi

147 Tissue factor pathway inhibitor (TFPI), the main inhibit

148 ld interact with and inhibit the activity of tissue factor pathway inhibitor (TFPI).

149 , endothelial protein C receptor (EPCR), and tissue factor pathway inhibitor (TFPI).

150 subjected the second Kunitz domain of human tissue factor pathway inhibitor 1 (TFPI1 D2) to directed

151 allenged with CpG DNA, and tissue factor and tissue factor pathway inhibitor expression and activity

152 lood cells, and an endogenous DPP4 inhibitor tissue factor pathway inhibitor has been discovered, inc

153 e factor, a key initiator of coagulation and tissue factor pathway inhibitor in human coronary artery

154 clot formation, decreasing upon induction of tissue factor pathway inhibitor or treatment with hirudi

155 r 9 shifted the balance of tissue factor and tissue factor pathway inhibitor toward procoagulant phen

156 Conversely, CpG DNA significantly reduced tissue factor pathway inhibitor transcription, secretion

157 natural anticoagulants protein C, protein S, tissue factor pathway inhibitor, and antithrombin.

158 bstitutive therapy as RNA interference, anti-tissue factor pathway inhibitor, and the gene therapy ai

159 tely abrogates the anticoagulant function of tissue factor pathway inhibitor, enhances fibrin clot st

160 , phospholipid transfer protein, matrilin-3, tissue factor pathway inhibitor, fibrinogen-like 1, and

161 tial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein C, plasminogen

162 ated FVIII), monoclonal antibodies targeting tissue factor pathway inhibitor, small interfering RNA t

163 n S, soluble endothelial protein C receptor, tissue factor pathway inhibitor, von Willebrand factor,

164 th factor activator inhibitor type 2 (HAI2), tissue factor pathway inhibitor-1 (TFPI1), and tissue fa

165 Similar disulfide engineering of tissue factor pathway inhibitor-1 Kunitz domain 1 ((KD1)

166 Tissue factor pathway inhibitor-2 (TFPI-2) is a homologu

167 ssue factor pathway inhibitor-1 (TFPI1), and tissue factor pathway inhibitor-2 (TFPI2), as well as E-

168 indirect mechanism by forming a complex with tissue factor pathway inhibitor-alpha (TFPIalpha), resul

169 d binds tightly to the coagulation regulator tissue factor pathway inhibitor-alpha (TFPIalpha).

170 n hemophilia, possibly through inhibition of tissue factor pathway inhibitor.

171 urally deleted (Kunitz 1-domainless) form of tissue factor pathway inhibitor.

172 TFPI2, a Kunitz-type serine protease in the tissue factor pathway that inhibits the initiation of th

173 We identified tissue-factor pathway inhibitor (TFPI) as a biological i

174 d 4-fold more activated platelet-derived and tissue-factor positive MVs respectively than control sub

175 creased levels of leukocytes, platelets, and tissue factor-positive (TF(+)) microvesicles (MVs) are a

176 .4% vs 1.2%, P = .002) and in proportions of tissue factor-positive patrolling (CD14(Dim)CD16(+)) mon

177 We found that ATG activated tissue factor procoagulant activity (TF PCA) on monocyti

178 t internalization, but had minimal impact on tissue factor procoagulant activity in vitro, were conju

179 an gather other proteins found in blood (eg, tissue factor procoagulant).

180 for monocyte matrix metalloproteinase-9 and tissue factor production and promote Ig production in au

181 for monocyte matrix metalloproteinase-9 and tissue factor production, as well as their cytolytic pot

182 mediate proliferation or elicit endothelial tissue factor production, confirming that these function

183 mediated coagulation pathways by diminishing tissue factor production, reducing plasma thrombin-antit

184 our results enlighten the mechanism by which tissue factor promotes tumor growth through PAR1, and th

185 Antibody-mediated inhibition of tissue factor reduced the clinical features of VT, the c

186 ion, macrophage pyroptosis, and accompanying tissue factor release, directly connecting inflammation

187 y thrombin, which, in turn, was activated by tissue factor released from intestinal macrophages.

188 uction of thrombin generation by infusion of tissue factor results in enhanced HK cleavage as a conse

189 mucosal dendritic cells and the gut-specific tissue factor retinoic acid (RA).

190 the aPC-mediated inhibition of inflammatory tissue-factor signaling.

191 Tissue factor-specific ADCs showed potent cytotoxicity i

192 ibody-drug conjugate (ADC), a panel of human tissue factor-specific antibodies (TF HuMab) was generat

193 electin (sE-Selectin), thrombomodulin (sTM), tissue factor (sTF) and vascular endothelial growth fact

194 Tissue factor (TF) (CD142) is a 47 kDa transmembrane cel

195 an blood under thrombotic flow conditions on tissue factor (TF) -bearing surfaces remains inadequatel

196 Increased plasma levels of NETs, tissue factor (TF) activity, and sC5b-9 were detected in

197 ecules plasminogen activator inhibitor-1 and tissue factor (TF) and increased platelet activation.

198 I (FVIIa) with zymogen factor VII (FVII) for tissue factor (TF) and loading of the platelet surface w

199 isplay varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant

200 mice activated the AHR pathway and augmented tissue factor (TF) and plasminogen activator inhibitor 1

201 Tissue factor (TF) and protease-activated receptor-1 (PA

202 lineate a role for coagulation signaling via tissue factor (TF) and proteinase-activated receptor 2 (

203 Herein, we demonstrate that inhibition of tissue factor (TF) and the downstream coagulation protea

204 overed the mechanism by which the complex of tissue factor (TF) and the plasma serine protease factor

205 rosine kinase and leads to the generation of tissue factor (TF) and thrombin.

206 ent induction of its downstream target genes tissue factor (TF) and vascular cell adhesion molecule-1

207 On the HSV1 surface, host-cell-derived tissue factor (TF) and virus-encoded glycoprotein C (gC)

208 ted whether plasma microparticles expressing Tissue Factor (TF) are increased in BS.

209 Previously, we have shown that inhibition of tissue factor (TF) attenuates activation of coagulation

210 Tissue factor (TF) binds the serine protease factor VIIa

211 The synthesis of tissue factor (TF) by monocytes/macrophages activated by

212 As microparticles expressing Tissue Factor (TF) can contribute to thrombosis in precl

213 We found that the extrinsic tissue factor (TF) coagulation initiation complex can se

214 prevent contact activation, over a range of tissue factor (TF) concentrations.

215 They are rescued by concomitant tissue factor (TF) deficiency, demonstrating that TFPI m

216 tigated the effects of the HIT Ab complex on tissue factor (TF) expression and release of TF-positive

217 yte interaction was strongly associated with tissue factor (TF) expression by the monocytes.

218 Tissue factor (TF) expression by tumor cells correlates

219 In the present study, we analyzed tissue factor (TF) expression in 4 different human pancr

220 In this study, we characterized tissue factor (TF) expression in mouse hepatocytes (HPCs

221 Brain death is also believed to increase tissue factor (TF) expression, contributing to a low rat

222 Some studies suggest that FVIIa requires tissue factor (TF) for function and that the reason for

223 separation of the membrane-anchored cofactor tissue factor (TF) from inactive precursors of coagulati

224 ment leads to a coordinated loss of EGFR and tissue factor (TF) from the plasma membrane and coincide

225 Overexpression of tissue factor (TF) has been associated with increased tu

226 Purpose Circulating tissue factor (TF) has been studied as a biomarker for p

227 duces expression of the procoagulant protein tissue factor (TF) in monocytes.

228 ecific prothrombotic metabolite that induces tissue factor (TF) in vascular smooth muscle cells (vSMC

229 sin-like serine protease, and membrane-bound tissue factor (TF) initiates blood coagulation upon vasc

230 Tissue factor (TF) is a cell-surface glycoprotein respon

231 Tissue factor (TF) is a cofactor for factor VIIa and the

232 Tissue factor (TF) is a critical mediator of direct acut

233 Tissue factor (TF) is a crucial mediator of injury-relat

234 Tissue factor (TF) is a transmembrane receptor and prima

235 TNBC treatment, we recently determined that tissue factor (TF) is a useful surface target in 50-85%

236 Tissue factor (TF) is aberrantly expressed in solid canc

237 Tissue factor (TF) is expressed in vascular and nonvascu

238 Although tissue factor (TF) is its natural receptor, rhFVIIa also

239 Tissue factor (TF) is the main initiator of the extrinsi

240 Tissue factor (TF) is the primary initiator of blood coa

241 Tissue factor (TF) is upregulated in many solid tumors,

242 n generation were drastically reduced in low tissue factor (TF) mice whereas the absence of factor XI

243 ration of prothrombin fragment 1+2 (PTF1.2), tissue factor (TF) mRNA synthesis, and monocyte TF expre

244 Klkb1(-/-) mice have reduced aortic tissue factor (TF) mRNA, antigen, and activity.

245 uced expression of the coagulation initiator tissue factor (TF) on innate immune cells.

246 Prior evidence indicates that induction of tissue factor (TF) on monocytes, a pivotal step in the i

247 Tissue factor (TF) pathway inhibitor (TFPI) is a well-ch

248 udies of the anticoagulant activities of the tissue factor (TF) pathway inhibitor (TFPI) isoforms, TF

249 riant in the human ADTRP [androgen-dependent tissue factor (TF) pathway inhibitor (TFPI) regulating p

250 It includes all reactions of the tissue factor (TF) pathway of coagulation through fibrin

251 The tissue factor (TF) pathway serves both hemostasis and ce

252 Tissue factor (TF) plays a central role in haemostasis a

253 cies-dependent proinflammatory signaling and tissue factor (TF) procoagulant activation.

254 usly showed that anti-GRP78 AutoAbs increase tissue factor (TF) procoagulant activity on the surface

255 Tissue factor (TF) signalling has been associated with a

256 Here, we aimed to investigate whether tissue factor (TF) was released by endothelial-derived e

257 ATP or UTP induces dramatic up-regulation of tissue factor (TF), a key initiator of the coagulation c

258 Here we report that EMT induces tissue factor (TF), a major cell-associated initiator of

259 Tissue factor (TF), a primary initiator of blood coagula

260 activation, pyroptotic macrophages released tissue factor (TF), an essential initiator of coagulatio

261 Caspase-11 enhanced the activation of tissue factor (TF), an initiator of coagulation, through

262 ncluding vascular endothelial growth factor, tissue factor (TF), and colony-stimulating factor 1.

263 In the absence of its cofactor tissue factor (TF), coagulation factor VIIa (FVIIa) pred

264 olecules, ectonucleotidases (CD39 and CD73), tissue factor (TF), endothelial-derived microparticle (E

265 r of coagulation, the transmembrane receptor tissue factor (TF), has gained considerable attention as

266 rystal structures of factor (F) VIIa/soluble tissue factor (TF), obtained under high Mg(2+) (50mM Mg(

267 ormal mice, expression levels of heparanase, tissue factor (TF), TF pathway inhibitor (TFPI), and TFP

268 vidence that tumor dormancy is influenced by tissue factor (TF), the cancer cell-associated initiator

269 severing bonds between the cytoskeleton and tissue factor (TF), the cell surface receptor responsibl

270 The aberrant expression of tissue factor (TF), the primary activator of coagulation

271 n, with consequent increased upregulation of tissue factor (TF), the primary initiator of blood coagu

272 -regulation of proinflammatory cytokines and tissue factor (TF), the principal initiator of the extri

273 f vascular effectors, including procoagulant tissue factor (TF), this study explores whether there is

274 on factors, von Willebrand factor (vWF), and tissue factor (TF), were demonstrated in constructs bear

275 ulation factor VIIa (FVIIa) and its cofactor tissue factor (TF), which converts FVIIa from an intrins

276 us FVIIa engages its cell-localized cofactor tissue factor (TF), which stimulates activity through me

277 ermediates make to prothrombin activation in tissue factor (Tf)-activated blood, immunoassays were de

278 Here we show in a tissue factor (TF)-dependent model of flow restriction-i

279 del of intravascular platelet deposition and tissue factor (TF)-initiated coagulation under flow is e

280 fferent types of membrane proteins, CorA and tissue factor (TF).

281 ation system through direct interaction with tissue factor (TF).

282 of prostaglandin (PG) E2, and the amount of tissue factor (TF).

283 ipid in myosin preparations may also contain tissue factor (TF).

284 Inhibitors of the tissue factor (TF)/factor VIIa complex (TF-FVIIa) are pr

285 d zymogen FX, with formation of a quaternary tissue factor (TF)/FVIIa/ FX(a)/Ixolaris inhibitory comp

286 patch of type I fibrillar collagen/lipidated tissue factor (TF; approximately 1 TF molecule/mum(2)),

287 via the intrinsic (FVIII-FIX) and extrinsic (tissue factor [TF]-FVII) coagulation pathways, as well a

288 xpression of the potent procoagulant protein tissue factor that triggers thrombosis.

289 t normal human neutrophils do not synthetize tissue factor, the initiator of the extrinsic pathway of

290 The tissue factor-thrombin-PAR-1 signaling axis in tumor cel

291 Our results indicate that the tissue factor/thrombin/PAR-1 pathway enhances IFN-beta e

292 esive surfaces in the absence or presence of tissue factor, thrombomodulin or activated protein C.

293 d activated partial thromboplastin times and tissue factor, tissue factor pathway inhibitor, protein

294 using platelet-rich plasma (PRP) showed that tissue factor-triggered thrombin generation was impaired

295 cent MPs promoted EC thrombogenicity through tissue factor upregulation, shedding of procoagulant MPs

296 , the primary host initiator of coagulation, tissue factor, was found to be dispensable for this anti

297 evels of thrombin-antithrombin complexes and tissue factor were measured.

298 tor (asTF) is a novel isoform of full-length tissue factor, which exhibits angiogenic activity.

299 man antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid

300 in-1, plasminogen activator inhibitor-1, and tissue factor, which positively correlated with fat mass